; and (4) in paragraph (4), by inserting , and $5,000,000 for fiscal year 2024 and each fiscal year thereafter, after 2010 . (b) Effective date The amendments made by this section take effect on the first day of the first quarter that begins on or after the date that is 18 months after the date of enactment of this Act. 7. OIG study and report on drug price mark-ups in Medicare part D Section 1860D–42 of the Social Security Act ( 42 U.S.C. 1395w–152 ) is amended by adding at the end the following new subsection: (e) OIG study and report on drug price mark-ups under this part (1) Study The Inspector General of the Department of Health and Human Services (in this subsection referred to as the Inspector General ) shall conduct a study on the impact of related party transactions within select vertically integrated entities on the negotiated price (as defined in section 1860D–2(d)(1)(B)) paid by part D plan sponsors for covered part D drugs. Such study may include an analysis of the following: (A) Acquisition costs by the affiliate within such vertically integrated entities that initially acquires the prescription drug for a sample of covered part D drugs, including at least 5 generic drugs, brand drugs, specialty brand drugs, and specialty generic drugs. (B) The methodologies and negotiation processes used to calculate transfer prices or other transactions between related parties with respect to such covered part D drugs. (C) The impact of the transactions described in subparagraph (B) on the negotiated price, net of direct and indirect remuneration, for such covered part D drugs. (D) The margin captured by different affiliates within such vertically integrated entities through the transactions described in subparagraph (B). (E) An assessment of the impact of the transactions described in subparagraph (B) on costs to individuals enrolled in a prescription drug plan or an MA–PD plan and program spending on prescription drugs under this part. (F) Other issues determined to be relevant and appropriate by the Inspector